Aspirin therapy for the prevention of pre-eclampsia in unselected women is minimally effective. New data suggest that use of a screening strategy based on clinical, biochemical and biophysical factors to identify those at high risk of pre-term pre-eclampsia could improve the efficacy of preventive aspirin therapy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Incidence and risk factors for Preeclampsia in a cohort of healthy nulliparous pregnant women: a nested case-control study
Scientific Reports Open Access 02 July 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Askie, L. M., Duley, L., Henderson-Smart, D. J., Stewart, L. A. & Group, P. C. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 369, 1791–1798 (2007).
Rolnik, D. L. et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N. Engl. J. Med. 377, 613–622 (2017).
Akolekar, R., Syngelaki, A., Poon, L., Wright, D. & Nicolaides, K. H. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn. Ther. 33, 8–15 (2013).
Roberge, S. et al. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet. Gynecol. 41, 491–499 (2013).
Roberge, S. et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am. J. Obstet. Gynecol. 216, 110–120.e6 (2017).
Ayala, D. E. et al. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol. Int. 30, 260–279 (2013).
U.S. Preventive Services Task Force et al. Screening for preeclampsia: US Preventive Services Task Force Recommendation Statement. JAMA 317, 1661–1667 (2017).
Werner, E. F. et al. A cost-benefit analysis of low-dose aspirin prophylaxis for the prevention of preeclampsia in the United States. Obstet. Gynecol. 126, 1242–1250 (2015).
Roberts, J. M. & Bell, M. J. If we know so much about preeclampsia, why haven't we cured the disease? J. Reprod. Immunol. 99, 1–9 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.M.R. is a consultant for Metabolomics, which is in the early stages of developing a diagnostic for pre-eclampsia. K.P.H. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Roberts, J., Himes, K. Screening and aspirin therapy for prevention of pre-eclampsia. Nat Rev Nephrol 13, 602–604 (2017). https://doi.org/10.1038/nrneph.2017.121
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2017.121